Exploiting computationally derived out-of-the-box protein conformations for drug design

Papers of special note have been highlighted as: •• of considerable interest

References

• 1 Wei G, Xi W, Nussinov R, Ma B. Protein ensembles: how does nature harness thermodynamic fluctuations for life? The diverse functional roles of conformational ensembles in the cell. Chem. Rev. 116(11), 6516–6551 (2016).
  Medline CASGoogle Scholar
• 2 Boehr DD, Nussinov R, Wright PE. The role of dynamic conformational ensembles in biomolecular recognition. Nat. Chem. Biol. 5(11), 789–796 (2009).
  Medline CASGoogle Scholar
• 3 Granier S, Kobilka B. A new era of GPCR structural and chemical biology. Nat. Chem. Biol. 8(8), 670–673 (2012).
  Medline CASGoogle Scholar
• 4 Nussinov R, Tsai C-J. Allostery without a conformational change? Revisiting the paradigm. Curr. Opin. Struct. Biol. 30, 17–24 (2015).
  Medline CASGoogle Scholar
• 5 Noble MEM, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 303(5665), 1800–1805 (2004).
  Medline CASGoogle Scholar
• 6 Endicott JA, Noble MEM. Structural characterization of the cyclin-dependent protein kinase family. Biochem. Soc. Trans. 41(4), 1008–1016 (2013).
  Medline CASGoogle Scholar
• 7 Nussinov R, Tsai C-J. Allostery in disease and in drug discovery. Cell 153(2), 293–305 (2013).
  Medline CASGoogle Scholar
• 8 Falchi F, Caporuscio F, Recanatini M. Structure-based design of small-molecule protein–protein interaction modulators: the story so far. Future Med. Chem. 6(3), 343–357 (2014).
  CASGoogle Scholar
• 9 Cheng T, Li Q, Zhou Z, Wang Y, Bryant SH. Structure-based virtual screening for drug discovery: a problem-centric review. AAPS J. 14(1), 133–141 (2012).
  Medline CASGoogle Scholar
• 10 Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr. Top. Med. Chem. 14(16), 1923–1938 (2014).
  Medline CASGoogle Scholar
• 11 Lounnas V, Ritschel T, Kelder J, McGuire R, Bywater RP, Foloppe N. Current progress in structure-based rational drug design marks a new mindset in drug discovery. Comput. Struct. Biotech. J. 5(6), 1–14 (2013).
  Google Scholar
• 12 Stumpfe D, Ripphausen P, Bajorath J. Virtual compound screening in drug discovery. Future Med. Chem. 4(5), 593–602 (2012).
  CASGoogle Scholar
• 13 Sgobba M, Caporuscio F, Anighoro A, Portioli C, Rastelli G. Application of a post-docking procedure based on MM-PBSA and MM-GBSA on single and multiple protein conformations. Eur. J. Med. Chem. 58, 431–440 (2012).
  Medline CASGoogle Scholar
• 14 Erickson JA, Jalaie M, Robertson DH, Lewis RA, Vieth M. Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. J. Med. Chem. 47(1), 45–55 (2004).
  Medline CASGoogle Scholar
• 15 RCSB. www.rcsb.org.
  Google Scholar
• 16 Sinko W, Lindert S, McCammon JA. Accounting for receptor flexibility and enhanced sampling methods in computer-aided drug design. Chem. Biol. Drug Des. 81(1), 41–49 (2013).
  Medline CASGoogle Scholar
• 17 Abrams C, Bussi G. Enhanced sampling in molecular dynamics using metadynamics, replica-exchange, and temperature-acceleration. Entropy 16(1), 163–199 (2013).
  Google Scholar
• 18 Schlick T. Molecular dynamics-based approaches for enhanced sampling of long-time, large-scale conformational changes in biomolecules. F1000 Biol. Rep. 1, 51 (2009).
  MedlineGoogle Scholar
• 19 Adcock SA, McCammon JA. Molecular dynamics: survey of methods for simulating the activity of proteins. Chem. Rev. 106(5), 1589–1615 (2006).
  Medline CASGoogle Scholar
• 20 Halgren T. New method for fast and accurate binding-site identification and analysis. Chem. Biol. Drug Des. 69(2), 146–148 (2007).
  Medline CASGoogle Scholar
• 21 Weisel M, Proschak E, Schneider G. PocketPicker: analysis of ligand binding-sites with shape descriptors. Chem. Cent. J. 1, 7 (2007).
  MedlineGoogle Scholar
• 22 Kalidas Y, Chandra N. PocketDepth: a new depth based algorithm for identification of ligand binding sites in proteins. J. Struct. Biol. 161(1), 31–42 (2008).
  Medline CASGoogle Scholar
• 23 Le Guilloux V, Schmidtke P, Tuffery P. Fpocket: an open source platform for ligand pocket detection. BMC Bioinformatics 10, 168 (2009).
  MedlineGoogle Scholar
• 24 Tripathi A, Kellogg GE. A novel and efficient tool for locating and characterizing protein cavities and binding sites. Proteins 78(4), 825–842 (2010).
  Medline CASGoogle Scholar
• 25 Tan KP, Varadarajan R, Madhusudhan MS. DEPTH: a web server to compute depth and predict small-molecule binding cavities in proteins. Nucleic Acids Res. 39, W242–W248 (2011).
  Medline CASGoogle Scholar
• 26 Schmidtke P, Bidon-Chanal A, Luque FJ, Barril X. MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories. Bioinformatics 27(23), 3276–3285 (2011).
  Medline CASGoogle Scholar
• 27 Laine E, Goncalves C, Karst JC et al. Use of allostery to identify inhibitors of calmodulin-induced activation of Bacillus anthracis edema factor. Proc. Natl Acad. Sci. USA 107(25), 11277–11282 (2010). •• Reports a prospective virtual screening application with the use of out-of-the-box protein conformations to identify new allosteric inhibitors.
  Medline CASGoogle Scholar
• 28 Laine E, Martínez L, Ladant D, Malliavin T, Blondel A. Molecular motions as a drug target: mechanistic simulations of anthrax toxin edema factor function led to the discovery of novel allosteric inhibitors. Toxins (Basel) 4(8), 580–604 (2012).
  Medline CASGoogle Scholar
• 29 Zhao H, Huang D, Caflisch A. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics. ChemMedChem 7(11), 1983–1990 (2012).
  Medline CASGoogle Scholar
• 30 Zhao H, Caflisch A. Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamics. Bioorg. Med. Chem. Lett. 23(20), 5721–5726 (2013).
  Medline CASGoogle Scholar
• 31 Morris GM, Huey R, Lindstrom W et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30(16), 2785–2791 (2009).
  Medline CASGoogle Scholar
• 32 Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J. Chem. Inf. Model. 52(7), 1757–1768 (2012).
  Medline CASGoogle Scholar
• 33 Lin Y-S, Bowman GR, Beauchamp KA, Pande VS. Investigating how peptide length and a pathogenic mutation modify the structural ensemble of amyloid beta monomer. Biophys. J. 102(2), 315–324 (2012).
  Medline CASGoogle Scholar
• 34 Xu Y, Shen J, Luo X et al. Conformational transition of amyloid beta-peptide. Proc. Natl Acad. Sci. USA 102(15), 5403–5407 (2005).
  Medline CASGoogle Scholar
• 35 Sgourakis NG, Merced-Serrano M, Boutsidis C et al. Atomic-level characterization of the ensemble of the Aβ(1–42) monomer in water using unbiased molecular dynamics simulations and spectral algorithms. J. Mol. Biol. 405(2), 570–583 (2011).
  Medline CASGoogle Scholar
• 36 Wang Y, Li L, Chen T, Chen W, Xu Y. Microsecond molecular dynamics simulation of Aβ42 and identification of a novel dual inhibitor of Aβ42 aggregation and BACE1 activity. Acta Pharmacol. Sin. 34(9), 1243–1250 (2013).
  Medline CASGoogle Scholar
• 37 Yang C, Li J, Li Y, Zhu X. The effect of solvents on the conformations of amyloid β-peptide (1–42) studied by molecular dynamics simulation. J. Mol. Struct. Theochem. 895(1), 1–8 (2009).
  CASGoogle Scholar
• 38 Tran L, Ha-Duong T. Exploring the Alzheimer amyloid-β peptide conformational ensemble: a review of molecular dynamics approaches. Peptides 69, 86–91 (2015).
  Medline CASGoogle Scholar
• 39 Martí-Solano M, Schmidt D, Kolb P, Selent J. Drugging specific conformational states of GPCRs: challenges and opportunities for computational chemistry. Drug Discov. Today 21(4), 625–631 (2016). •• A perspective on the pros and challenges of targeting distinct conformational states in G-protein-coupled receptor drug discovery.
  Medline CASGoogle Scholar
• 40 Okram B, Nagle A, Adrián FJ et al. A general strategy for creating “inactive-conformation” abl inhibitors. Chem. Biol. 13(7), 779–786 (2006).
  Medline CASGoogle Scholar
• 41 Geppetti P, Veldhuis NA, Lieu T, Bunnett NW. G protein-coupled receptors: dynamic machines for signaling pain and itch. Neuron 88(4), 635–649 (2015).
  Medline CASGoogle Scholar
• 42 Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 53, 531–556 (2013).
  Medline CASGoogle Scholar
• 43 Kohlhoff KJ, Shukla D, Lawrenz M et al. Cloud-based simulations on Google Exacycle reveal ligand modulation of GPCR activation pathways. Nat. Chem. 6(1), 15–21 (2014). •• Describes a protocol to reconstruct activation pathways and identify out-of-the-box protein conformations based on molecular dynamics (MD) and Markov state models.
  Medline CASGoogle Scholar
• 44 Shukla D, Lawrenz M, Pande VS. Elucidating ligand-modulated conformational landscape of GPCRs using cloud-computing approaches. Meth. Enzymol. 557, 551–572 (2015).
  Medline CASGoogle Scholar
• 45 Bowman GR, Geissler PL. Equilibrium fluctuations of a single folded protein reveal a multitude of potential cryptic allosteric sites. Proc. Natl Acad. Sci. USA 109(29), 11681–11686 (2012).
  Medline CASGoogle Scholar
• 46 Bowman GR, Bolin ER, Hart KM, Maguire BC, Marqusee S. Discovery of multiple hidden allosteric sites by combining Markov state models and experiments. Proc. Natl Acad. Sci. USA 112(9), 2734–2739 (2015).
  Medline CASGoogle Scholar
• 47 Shukla D, Meng Y, Roux B, Pande VS. Activation pathway of Src kinase reveals intermediate states as targets for drug design. Nat. Commun. 5, 3397 (2014). •• Reports a protocol to reconstruct activation pathways and identify intermediate states based on MD and Markov state models.
  MedlineGoogle Scholar
• 48 Betzi S, Alam R, Martin M et al. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem. Biol. 6(5), 492–501 (2011).
  Medline CASGoogle Scholar
• 49 Palmieri L, Rastelli G. αC helix displacement as a general approach for allosteric modulation of protein kinases. Drug Discov. Today 18(7), 407–414 (2013).
  Medline CASGoogle Scholar
• 50 Yang S, Banavali NK, Roux B. Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories. Proc. Natl Acad. Sci. USA 106(10), 3776–3781 (2009).
  Medline CASGoogle Scholar
• 51 Rastelli G, Anighoro A, Chripkova M, Carrassa L, Broggini M. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2. Cell Cycle 13(14), 2296–2305 (2014).
  Medline CASGoogle Scholar
• 52 Pisani P, Caporuscio F, Carlino L, Rastelli G. Molecular dynamics simulations and classical multidimensional scaling unveil new metastable states in the conformational landscape of CDK2. PLoS ONE 11(4), e0154066 (2016). •• Describes a protocol to map protein conformational landscapes and identify out-of-the-box protein conformations based on classical and accelerated MD and classical multidimensional scaling.
  MedlineGoogle Scholar
• 53 Atzori A, Bruce NJ, Burusco KK, Wroblowski B, Bonnet P, Bryce RA. Exploring protein kinase conformation using swarm-enhanced sampling molecular dynamics. J. Chem. Inf. Model. 54(10), 2764–2775 (2014). •• Presents a protocol to identify intermediate protein conformations based on swarm-enhanced sampling molecular dynamics.
  Medline CASGoogle Scholar
• 54 Cavasotto CN, Phatak SS. Homology modeling in drug discovery: current trends and applications. Drug Discov. Today 14(13), 676–683 (2009).
  Medline CASGoogle Scholar